Pharvaris N.v. · NASDAQ:PHVS
Pharvaris — Investor Presentation (January 2026)
26 slides from Pharvaris's investor presentation, Jan 12, 2026
Slide 1: Pioneering science for patient choice
Pioneering science for patient choice Corporate Presentation January 2026 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-l
Slide 3: Deucrictibant: Pioneering science for patient choice in AE-BK
Orphan drug designation in the U.S. and Europe1,2 Robust IP on CoM (granted in multiple territories, initial term to 2038) and formulations3,4 DEUCRICTIBANT Pioneering science for patient choice in AE-BK Notes: AE-BK: bradykinin-mediated angioedema. HAE: hereditary angioedema. AAE-C1INH: acquired an
Slide 4: Bradykinin-mediated angioedema: painful, unpredictable swelling with significant unmet need
Bradykinin-mediated angioedema: a disease of painful, unpredictable swelling with significant unmet need Notes: HAE: hereditary angioedema. Source: 1Bork K et al. Allergy Asthma Clin Immunol. 2021. 2Mendivil J et al. Orphanet J Rare Dis. 2021. Data reported from a web-based, multinational patient su
Slide 5: First-to-market does not guarantee long-term market leadership
First-to-market does not guarantee long-term market leadership Note: HAE: hereditary angioedema. LTP: long-term prophylaxis. ODT: on-demand therapy. Source: 1Evaluate Pharma uptake curves 2008-2024. 2SEC filings (BioCryst, CSL Behring, Pharming, Takeda). Dynamic market supports medicines that improv
Slide 6: Pricing corridors for HAE branded products remain favorable
Pricing corridors for HAE branded products remain favorable Current pricing dynamics in the U.S. Annual WAC for currently approved LTPs Current Pricing* WAC per attack for currently approved ODTs Current Pricing* Note: HAE: hereditary angioedema. LTP: long-term prophylaxis. ODT: on-demand therapy. W
Slide 7: U.S. HAE market is expected to grow over the next decade
In line with treatment guidelines, the U.S. HAE market is expected to grow over the next decade Notes: HAE: hereditary angioedema. LTP: long-term prophylaxis. ODT: on-demand therapy. CAGR: compound annual growth rate. Source: 1Maurer M, et al. Allergy. 2022. 2IQVIA market evolution and company data.
Slide 8: Bradykinin B2 receptor antagonism is a foundational mechanism
Bradykinin B2 receptor antagonism is a foundational mechanism to prevent and treat bradykinin-mediated angioedema attacks1,2 Note: AE-BK: bradykinin-mediated angioedema. ACE: angiotensin-converting enzyme. ACEi: ACE inhibitor. cHMWK: cleaved high molecular weigh kininogen. FXII: factor XII. FXIIa: a
Slide 9: Deucrictibant potential to address unmet needs in bradykinin-mediated angioedema
Deucrictibant has the potential to address unmet needs of people living with bradykinin-mediated angioedema Notes: AE-BK: bradykinin-mediated angioedema. Source: 1Zhang Z et al. C1INH WS 2025. 2Lesage A et al. IDDST 2024. 3Zhang Z et al. ACAAI 2025. 4NCT06669754. 5Crabbe et al. AAAAI 2021. 6Maurer M
Slide 10: Deucrictibant differentiated profile for LTP and ODT
Deucrictibant differentiated profile for LTP and ODT ODT Oral LTP or ODT formulations Single oral pill Rapid to steady state Rapid absorption Durable effective exposure Deucrictibant is the only HAE drug1 in development that allows for oral administration in both prophylaxis and on-demand2 Deucricti
Slide 11: Wholly-owned pipeline focused on bradykinin B2 receptor mechanism
Wholly-owned pipeline focused on bradykinin B2 receptor mechanism Notes: AAE-C1INH: acquired angioedema due to C1 inhibitor deficiency. HAE: hereditary angioedema. OLE: open-label extension. Source: RAPIDe-1 (NCT04618211). RAPIDe-2 (NCT05396105). RAPIDe-3 (NCT06343779). CHAPTER-1 (NCT05047185). CHAP
Slide 12: Deucrictibant clinical development program
HAE On-Demand Treatment (ODT) HAE Long-Term Prophylaxis (LTP) Deucrictibant clinical development program Notes: HAE: hereditary angioedema. OLE: open-label extension. AAE-C1INH: acquired angioedema due to C1 inhibitor deficiency. Source: 1NCT05047185. 2NCT06669754. 3NCT06679881. 4NCT04618211. 5NCT05
Slide 13: On-Demand: Deucrictibant immediate-release capsules
On-Demand Deucrictibant immediate-release capsules
Slide 14: People with HAE want effective on-demand therapies in oral form
People with HAE want effective on-demand therapies in a well-tolerated, convenient oral form Notes: HAE: Hereditary Angioedema. ODT: On-Demand Treatment. Sources: 1Betschel SD et al. Allergy Asthma Clin Immunol. 2024. 2Christiansen S et al. Ann Allergy Asthma Immunol. 2024. 3Bernstein JA et al. J Ma
Slide 15: RAPIDe-3 data confirm rapid symptom relief and complete resolution
RAPIDe-3 data confirm rapid symptom relief and complete symptom resolution of deucrictibant* Notes: * vs placebo, median time to event; outcomes of placebo-treated attacks (not visualized) refer to data on file. aEnd of Progression (EoP): defined as the earliest post-treatment timepoint after which
Slide 16: Long-Term Prophylaxis: Deucrictibant extended-release tablets
Long-Term Prophylaxis Deucrictibant extended-release tablets
Slide 17: People with HAE are seeking effective, convenient prophylactic therapies
People with HAE are seeking highly effective, well-tolerated and convenient prophylactic therapies Notes: * ~7% of patients switch LTPs and ~13% of patients discontinue their LTP; † Switching data obtained from analysis of 1,149 patients with 12 months to 6.5 years of continuous coverage; ‡Vomiting,
Slide 18: Deucrictibant potential to sustain control of HAE attacks
Deucrictibant has the potential to sustain control of HAE attacks, with injectable-like efficacy™ and placebo-like tolerability Notes: The term injectable-like efficacy is a registered trademark of Pharvaris GmBH; Mean monthly rates based on time-normalized number of attacks per 4 weeks; *40 mg data
Slide 19: XR formulation maintains therapeutic exposure for over 24 hours
XR formulation maintains therapeutic exposure level for over 24 hours Note: XR: extended-release tablet formulation of deucrictibant. IR: immediate-release capsule formulation of deucrictibant. Source: 1Zhang Z et al. C1-INH WS 2025. 2Maurer M et al. C1-INH Workshop 2023. 3Lesage A et al. ACAAI 2022
Slide 20: CHAPTER-3 and CHAPTER-4 study designs
CHAPTER-3 and CHAPTER-4 study designs Notes: HAE: hereditary angioedema. XR: extended-release tablet. Source: Zanichelli A et al. C1-INH WS 2025. Global Phase 3 studies of deucrictibant for prophylaxis of HAE attacks CHAPTER-3 Enrollment Target enrollment of approximately 81 adolescents and adults l
Slide 21: Acquired Angioedema due to C1-Inhibitor Deficiency (AAE-C1INH)
Acquired Angioedema due to C1-Inhibitor Deficiency (AAE-C1INH)
Slide 22: Bradykinin B2 receptor antagonism broadly applicable across angioedema
Bradykinin B2 receptor antagonism broadly applicable across angioedema Notes: bold = known or potential role for bradykinin involvement in disease. †also designated as Normal C1INH Angioedema (HAE-nC1INH). HMWK: high-molecular-weight kininogen; cHMWK: cleaved high-molecular-weight kininogen; FXII(a)
Slide 23: CREAATE: deucrictibant for treatment of AAE-C1INH
CREAATE: deucrictibant for treatment of AAE-C1INH Pivotal, global Phase 3 for both prophylaxis and on-demand treatment R Deucrictibant XR tablet 40 mg/day Screening Placebo R Deucrictibant IR capsule 20 mg Placebo Deucrictibant IR capsule 20 mg Placebo Deucrictibant IR capsule 20 mg Screening Part 1
Slide 24: Pharvaris Vision
Pharvaris Vision PHARVARiS ©2026 24
Slide 25: Our aspiration is to become a bradykinin-mediated angioedema market leader
Our aspiration is to become a bradykinin-mediated angioedema market leader Notes: Aspirational, to be confirmed with Phase 3 clinical data. AE-BK: bradykinin-mediated angioedema. ODT: on-demand therapy. LTP: long-term prophylaxis. B2R: B2 receptor. MOA: mechanism of action. 1 2 4 3 Win the oral LTP
Slide 26: www.pharvaris.com
www.pharvaris.com NASDAQ: PHVS